Institution
Université catholique de Louvain
Education•Louvain-la-Neuve, Belgium•
About: Université catholique de Louvain is a education organization based out in Louvain-la-Neuve, Belgium. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 25319 authors who have published 57360 publications receiving 2172080 citations. The organization is also known as: University of Louvain & UCLouvain.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The existence of antibiotic efflux pumps, and their impact on therapy, must be taken fully into account for the selection of novel antimicrobials, and the design of specific, potent inhibitors appears to be an important goal for the improved control of infectious diseases in the near future.
391 citations
••
TL;DR: The neurodegeneration observed in Friedreich's ataxia can be well explained on the basis of a mitochondrial iron overload responsible for an increased production of highly toxic free radicals.
391 citations
••
TL;DR: In this article, a comprehensive understanding of the fundamentals of the microstructural evolution during FSW/P has been developed, including the mechanisms underlying the development of grain structures and textures, phases, phase transformations and precipitation.
390 citations
••
TL;DR: At presentation, the symptoms seen with AFBs do not differ according to the age of the patient; however, the delay to diagnosis, the location of the AFBs, and the radiographic images differ between child and adult populations.
390 citations
••
Institut Gustave Roussy1, University of Bordeaux2, Medisch Spectrum Twente3, Claude Bernard University Lyon 14, University of Paris5, Erasmus University Rotterdam6, Université catholique de Louvain7, Radboud University Nijmegen8, Leiden University9, Utrecht University10, University of Caen Lower Normandy11, Katholieke Universiteit Leuven12, Instituto Nacional de Saúde Dr. Ricardo Jorge13, Netherlands Cancer Institute14
TL;DR: Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features and in patients with unfavorable features, four courses of chemotherapyplus involved- field radiotherapy ought to be thestandard treatment.
Abstract: BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) combined with doxorubicin, bleomycin, and vinblastine (ABV) plus involved-field radiotherapy with subtotal nodal radiotherapy alone (reference group). In the H8-U trial, we compared three regimens: six cycles of MOPP-ABV plus involved-field radiotherapy (reference group), four cycles of MOPP-ABV plus involved-field radiotherapy, and four cycles of MOPP-ABV plus subtotal nodal radiotherapy. RESULTS: The median follow-up was 92 months. In the H8-F trial, the estimated 5-year event-free survival rate was significantly higher after three cycles of MOPP-ABV plus involved-field radiotherapy than after subtotal nodal radiotherapy alone (98% vs. 74%, P<0.001). The 10-year overall survival estimates were 97% and 92%, respectively (P=0.001). In the H8-U trial, the estimated 5-year event-free survival rates were similar in the three treatment groups: 84% after six cycles of MOPP-ABV plus involved-field radiotherapy, 88% after four cycles of MOPP-ABV plus involved-field radiotherapy, and 87% after four cycles of MOPP-ABV plus subtotal nodal radiotherapy. The 10-year overall survival estimates were 88%, 85%, and 84%, respectively. CONCLUSIONS: Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features. In patients with unfavorable features, four courses of chemotherapy plus involved-field radiotherapy should be the standard treatment. (ClinicalTrials.gov number, NCT00379041 [ClinicalTrials.gov].).
389 citations
Authors
Showing all 25540 results
Name | H-index | Papers | Citations |
---|---|---|---|
Robert Langer | 281 | 2324 | 326306 |
Pulickel M. Ajayan | 176 | 1223 | 136241 |
Klaus Müllen | 164 | 2125 | 140748 |
Giacomo Bruno | 158 | 1687 | 124368 |
Willem M. de Vos | 148 | 670 | 88146 |
David Goldstein | 141 | 1301 | 101955 |
Krzysztof Piotrzkowski | 141 | 1269 | 99607 |
Andrea Giammanco | 135 | 1362 | 98093 |
Christophe Delaere | 135 | 1320 | 96742 |
Vincent Lemaitre | 134 | 1310 | 99190 |
Michael Tytgat | 134 | 1449 | 94133 |
Jian Li | 133 | 2863 | 87131 |
Jost B. Jonas | 132 | 1158 | 166510 |
George Stephans | 132 | 1337 | 86865 |
Peter Hall | 132 | 1640 | 85019 |